JANSSEN PHARMACEUTICA ANNOUNCES COLLABORATION WITH VERTEX PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE VX-950 FOR TREATMENT OF HEPATITIS C

A A

Johnson & Johnson announced today that Janssen Pharmaceutica N.V., a Johnson & Johnson company, has entered into a collaboration with Vertex Pharmaceuticals Incorporated to develop and commercialize Vertex's investigational hepatitis C virus (HCV) protease inhibitor, VX-950. Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=410842)